Tarlatamab + Durvalumab
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small-Cell Lung Cancer
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Trial Timeline
Jun 5, 2024 → Sep 30, 2028
NCT ID
NCT06211036About Tarlatamab + Durvalumab
Tarlatamab + Durvalumab is a phase 3 stage product being developed by Amgen for Extensive-Stage Small-Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06211036. Target conditions include Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06211036 | Phase 3 | Active |
Competing Products
20 competing products in Extensive-Stage Small-Cell Lung Cancer